Shilpa Medicare share price, P/E, ROE & financials

On 6 Nov 2026, Shilpa Medicare was priced at ₹942.35, or 55.2× trailing earnings, against an industry P/E of 28.7×, and the shares are 14% below their 52-week high. Sales grew 14% a year over 3 years; its ROCE of 12% is the second-lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. Debt is 0.24× equity, and its dividend yield is 0.1%. It is a small-cap company with a market cap of ₹18,431 Cr, ranked 23rd of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 158% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year

Open: ₹901.85
Day high: ₹969.80
Day low: ₹901.85
Prev. close: ₹921.80
Volume: 12 L

Health check

3 good · 3 to check

ReturnsAhead
+157.8% over a year, better than 7 of 7 peers.
Price tagPricier
P/E 55.2 vs industry 28.7.
GrowthStrong
Sales +13.8% a year over 3 years.
ProfitabilityWeak
ROCE 12.0% vs peer median 17.9%.
Balance sheetSolid
Debt 0.24× equity, interest covered 7.3×, Piotroski 7 of 9.
Red flags2 to check
P/E of 55.2 against an industry P/E of 28.7.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹18,431 Cr, #23 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹1,847 Cr · profit ₹332 Cr

Market cap: ₹18,431 Cr; Small cap
P/E: 55.2; Industry 28.7
Price to book: 6.68; Peers 4.99
Dividend yield: 0.06%
ROE: 12.8%; Peers 14.7%
ROCE: 12.0%; Peers 17.9%
Debt to equity: 0.24; Debt ₹666 Cr
EPS (TTM): ₹17.08; Face value ₹1
OPM (TTM): 27.8%; Net margin 18.0%
Sales growth: +43.0%; Latest quarter vs a year ago
Profit growth: +79.7%; Latest quarter vs a year ago
Price to sales: 9.98; EV/EBITDA 41.2

Strengths

Quarterly profit up 79.7% on a year ago.
Quarterly sales up 43.0% on a year ago.
Positive operating cash flow in each of the last 4 years.

Risks to check

P/E of 55.2 against an industry P/E of 28.7.
Promoter stake down from 44.2% to 40.1%.

Derived automatically from reported figures. Not a recommendation.

About Shilpa Medicare

Shilpa Medicare Limited offers pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation (CDMO) services in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib,…

Headquarters: Raichur
Employees: 1,241
Sector: Healthcare
ISIN: INE790G01031
Website: vbshilpa.com

Price range

52 weeks

₹259.50₹1,095.00

Today

₹901.85₹969.80

Avg volume (3M): 11.5 L
1-year return: plus 157.8%
From 52-week high: minus 13.9%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
SHILPAMEDShilpa Medicare	942.35	plus 2.23%	18,431	55.2	6.68	12.0%	9.8%	21.7%	13.8%	–	0.06%	plus 157.8%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
370	410	437	466	529
262	295	317	330	387
108	114	120	136	142
29.3%	27.9%	27.4%	29.3%	26.9%
1.4	0.5	20	9.1	8.5
15.7	10.7	30.6	12.1	12.7
29.8	30.4	13.7	35.2	34.3
–	−12.9	25	–	−0.4
64.4	60.9	120	98.1	104
31.6%	26.7%	10.5%	−2.9%	23.5%
44.1	44.6	108	101	79.2
2.25	2.36	5.51	5.16	4.05

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +13.8%
ROE: 12.8%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
1,043	1,152	1,285	1,538
–	+10.4%	+11.6%	+19.7%
953	910	972	1,148
90.9	242	313	390
8.7%	21.0%	24.3%	25.4%
23.6	−1.9	29.5	74.4
56.3	83.7	75.5	46.6
95.5	108	113	120
−1.1	6.1	−31.4	−3
−38.3	54.3	122	295
19.1%	41.2%	36.0%	17.6%
−32.5	31.9	78.3	243
–	–	+145.6%	+210.8%
-1.88	1.83	4.02	12.44

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
8.7	8.7	9.8	19.6
1,775	1,792	2,353	2,572
798	937	588	660
323	355	360	455
2,904	3,093	3,311	3,706
1,588	1,638	1,707	1,818
408	445	494	468
13.4	28.9	0.2	19.9
22.2	30.2	25.6	41.3
872	950	1,084	1,359
2,904	3,093	3,311	3,706

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
180	137	132	342
−233	−167	−199	−326
45.8	46.8	62.7	13.6
−6.9	16.9	−4.2	29.9
−227	−185	−244	−371
−46.7	−47.9	−111	−28.5
−9.5	–	–	−9.8

Shareholding pattern

Source: NSE filings

40.1%

promoters

Promoters40.13%
Public59.87%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	40.13%	59.87%	0.00
30 Jun 2026	40.13%	59.87%	0.00
31 Mar 2026	40.13%	59.87%	0.00
31 Dec 2025	40.13%	59.87%	minus 4.10
30 Sep 2025	44.23%	55.77%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you